Cardiometabolic & kidneyMeta-analysis
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
- Pre-specified participant-level pooled analysis of randomised trials
- 3 RCTs (FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF)
Authors' conclusion
While in this pooled analysis the reduction in cardiovascular death was not statistically significant, finerenone reduced the risks for deaths of any cause, cardiovascular events and kidney outcomes.
Study context
- Population
- Patients with cardiovascular-kidney-metabolic syndrome (HF and CKD with T2DM)
- Participants
- 18,991 patients · 3 RCTs
- Comparison
- Finerenone vs placebo
- Outcome
- CV death
- Follow-up
- Median 2.9 years
Pooled result
As reported in the abstract
median 2.9 years
Hazard ratio
0.89
95% CI 0.78–1.01
P = 0.076
Events by group
Finerenone vs Placebo
HR 0.89 (95% CI 0.78–1.01); P = 0.076
Further pooled results
| Outcome | Finerenone | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause death | 11.0% | 12.0% | 0.91 (0.84–0.99) | P = 0.027 | |
| HF hospitalization | 0.83 (0.75–0.92) | P < 0.001 | |||
| Composite kidney outcome | 0.80 (0.72–0.90) | P < 0.001 | |||
| 0.512Hazard ratio (log scale) |
Original publication
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. Published 1 September 2024. doi:10.1038/s41591-024-03264-4
Summarised from the published abstract; every number is checked against it